

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 September 2022 (09.09.2022)



(10) International Publication Number
WO 2022/187403 A1

(51) International Patent Classification:

A61K 31/4184 (2006.01) C07D 235/06 (2006.01)
C07D 235/04 (2006.01) C07D 403/12 (2006.01)

(21) International Application Number:

PCT/US2022/018575

(22) International Filing Date:

02 March 2022 (02.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/156,227 03 March 2021 (03.03.2021) US

(71) Applicant: **TERNS PHARMACEUTICALS, INC.**
[US/US]; 1065 E. Hillsdale Blvd., Suite 100, Foster City,
California 94404 (US).

(72) Inventors: **KIRSCHBERG, Thorsten A.**; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). **REEVES, Corey**; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). **KLUCHER, Kevin**; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). **FENAUX, Martijn**; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). **XU, Yingzi**; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). **ROMERO, F. Anthony**; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). **HALCOMB, Randall**; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US).

(74) Agent: **SNYDER, Seth et al.**; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS

(57) Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders ameliorated by activation of THR beta.

WO 2022/187403 A1